Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression

Cancer Genetics

Volumn 205, Issue 12, 2012, Pages 630-635

  Flora, Marcella ^a   Piana, Simonetta ^a   Bassano, Cristina ^a   Bisagni, Alessandra ^a   De Marco, Loredana ^a   Ciarrocchi, Alessia ^a   Tagliavini, Elena ^a   Gardini, Giorgio ^a   Tamagnini, Ione ^a   Banzi, Chiara ^a   Bisagni, Giancarlo ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Colorectal cancer; EGFR; Fluorescence in situ hybridization; Gene copy number

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SCREENING; COLON RESECTION; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DYSPLASIA; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION;

ADENOMA; AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84872016455     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.10.005     Document Type: Article

References (35)

1. Hemming A.W., Davis N.L., Kluftinger A., et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and KI-67. J Surg Oncol 1992, 51:147-152.
2. Kluftinger A., Robinson B.W., Quenville N.F., et al. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992, 1:97-105.
3. Mayer A., Takimoto M., Fritz E., et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460.
4. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
5. Spano J.P., Lagorce C., Atlan A., et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005, 16:102-108.
6. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
7. Metro G., Finocchiaro G., Cappuzzo F. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol 2008, 17(Suppl 2):ii42-ii45.
8. Fichera A., Little N., Jagadeeswaran S., et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007, 67:827-835.
9. Dougherty U., Sehdev A., Cerda S., et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008, 14:2253-2262.
10. Bansal A., Liu X., McGregor D.H., et al. Correlation of epidermal growth factor receptor with morphological features of colorectal advanced adenomas: a pilot correlative case series. Am J Med Sci 2010, 340:296-300.
11. Jaszewski R., Levi E., Sochacki P., et al. Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis. Cancer Lett 2004, 213:249-255.
12. Hayashi Y., Widjono Y.W., Ohta K., et al. Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol Int 1994, 44:124-130.
13. Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000, 21:105-115.
14. Quirke P., Risio M., Lambert R., et al. Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch 2011, 458:1-19.
15. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245.
16. Zlobec I., Raineri I., Schneider S., et al. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung Cancer 2010, 68:192-197.
17. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
18. Cappuzzo F., Finocchiaro G., Rossi E., et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008, 19:717-723.
19. Sartore-Bianchi A., Bencardino K., Di Nicolantonio F., et al. Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 2010, 5:19-28.
20. Corpet D.E., Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003, 12:391-400.
21. Atkins D., Reiffen K.A., Tegtmeier C.L., et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissue: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004, 52:893-901.
22. Kersting C., Packeisen J., Leidinger B., et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 2006, 59:585-590.
23. Martin V., Mazzucchelli L., Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009, 62:314-324.
24. Ooi A., Takehna T., Li X., et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004, 17:895-904.
25. Capuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefinitib sensitivity in non-small-cell cancer. J Natl Cancer Inst 2005, 97:643-655.
26. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23:6838-6845.
27. Sauer T., Guren M.G., Noren T., et al. Demonstration of EGFR gene copy loss in colorectal carcinoma by fluorescent in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. Histopathology 2005, 47:560-564.
28. Frattini M., Saletti P., Romagnani V., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
29. Capuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer 2008, 60:160-165.
30. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
31. Italiano A., Follana P., Caroli F.X., et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR copy number. Ann Surg Oncol 2008, 15:649-654.
32. Personeni N., Fieuws S., Piessevaux H., et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876.
33. Scartozzi M., Bearzi I., Mandolesi A., et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009, 9:303.
34. van Krieken J.H., Jung A., Kirchner T., et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453:417-431.
35. Eberhard D.A., Giaccone G., Johnson B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-984.